VEGFA and hepatocellular carcinoma: In 2020, a phase III trial of the immune checkpoint inhibitor Atezolizumab with the vascular endothelial growth factor (VEGF) monoclonal antibody Bevacizumab in patients with unresectable HCC was conducted [32].